Marinomed Biotech AG confirmed its financial outlook for the fiscal year 2022: The Company expects continued growth of Carragelose revenues and a slight increase in R&D expenses, and consequently an operating loss for 2022. Marinomed plans to reach operating profitability in the medium term.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.8 EUR | -3.40% | -6.23% | -56.16% |
May. 22 | Transcript : Marinomed Biotech AG, Q1 2024 Earnings Call, May 22, 2024 | |
May. 21 | Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-56.16% | 22.06M | |
-0.46% | 91.94B | |
-3.16% | 38.74B | |
+64.83% | 26.66B | |
-13.98% | 15.32B | |
-5.40% | 13.3B | |
-11.38% | 11.65B | |
+156.85% | 10.37B | |
-49.84% | 10.12B | |
+2.32% | 9.06B |
- Stock Market
- Equities
- MARI Stock
- News Marinomed Biotech AG
- Marinomed Biotech AG Confirms Financial Outlook for the Fiscal Year 2022